p16 Hypermethylation and KRASMutation Are Independent Predictors of Cetuximab Plus FOLFIRI Chemotherapy in Patients with Metastatic Colorectal Cancer
1
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Purpose Hypermethylation of the CpG island of p16INK4a occurs in a significant proportion of colorectal cancer (CRC). We aimed to investigate its predictive role in CRC patients treated with 5-fluorouracil, leucovorin, irinotecan (FOLFIRI), and cetuximab. Materials and Methods Pyrosequencing was used to identify KRAS mutation and hypermethylation of 6 CpG island loci (p16, p14, MINT1, MINT2, MINT31, and hMLH1) in DNA extracted from formalin-fixed paraffin-embedded specimens. Logistic regression and Cox regression were performed for analysis of the relation between methylation status of CpG island methylator phenotype (CIMP) markers including p16 and clinical outcome. Results Hypermethylation of the p16 gene was detected in 14 of 49 patients (28.6%) and showed significant association with KRAS mutation (Fisher exact, p=0.01) and CIMP positivity (Fisher exact, p=0.002). Patients with p16-unmethylated tumors had significantly longer time to progression (TTP; median, 9.0 months vs. 3.5 months; log-rank, p=0.001) and overall sur- vival (median, 44.9 months vs. 16.4 months; log-rank, p=0.008) than those with p16-methy- lated tumors. Patients with both KRAS and p16 aberrancy (n=6) had markedly shortened TTP (median, 2.8 months) compared to those with either KRAS or p16 aberrancy (n=11; median, 8.6 months; p=0.021) or those with neither (n=32; median, 9.0 months; p < 0.0001). In multivariate analysis, KRAS mutation and p16 methylation showed inde- pendent association with shorter TTP (KRAS mutation: hazard ratio [HR], 3.21; p=0.017; p16 methylation: HR, 2.97; p=0.027). Conclusion Hypermethylation of p16 was predictive of clinical outcome in metastatic CRC patients treated with cetuximab and FOLFIRI, irrespective of KRAS mutation.
Abstract
Purpose Hypermethylation of the CpG island of p16INK4a occurs in a significant proportion of colorectal cancer (CRC). We aimed to investigate its predictive role in CRC patients treated with 5-fluorouracil, leucovorin, irinotecan (FOLFIRI), and cetuximab. Materials and Methods Pyrosequencing was used to identify KRAS mutation and hypermethylation of 6 CpG island loci (p16, p14, MINT1, MINT2, MINT31, and hMLH1) in DNA extracted from formalin-fixed paraffin-embedded specimens. Logistic regression and Cox regression were performed for analysis of the relation between methylation status of CpG island methylator phenotype (CIMP) markers including p16 and clinical outcome. Results Hypermethylation of the p16 gene was detected in 14 of 49 patients (28.6%) and showed significant association with KRAS mutation (Fisher exact, p=0.01) and CIMP positivity (Fisher exact, p=0.002). Patients with p16-unmethylated tumors had significantly longer time to progression (TTP; median, 9.0 months vs. 3.5 months; log-rank, p=0.001) and overall sur- vival (median, 44.9 months vs. 16.4 months; log-rank, p=0.008) than those with p16-methy- lated tumors. Patients with both KRAS and p16 aberrancy (n=6) had markedly shortened TTP (median, 2.8 months) compared to those with either KRAS or p16 aberrancy (n=11; median, 8.6 months; p=0.021) or those with neither (n=32; median, 9.0 months; p < 0.0001). In multivariate analysis, KRAS mutation and p16 methylation showed inde- pendent association with shorter TTP (KRAS mutation: hazard ratio [HR], 3.21; p=0.017; p16 methylation: HR, 2.97; p=0.027). Conclusion Hypermethylation of p16 was predictive of clinical outcome in metastatic CRC patients treated with cetuximab and FOLFIRI, irrespective of KRAS mutation.
참고문헌 (25)
- Fearon ER, "A genetic model for colorectal tumorigenesis", Cell, 61, pp.759~767 (1990)
- Jass JR, "Classification of colorectal cancer based on correlation of clinical, morphological and molecular features", Histopathology, 50, pp.113~130 (2007)
- Kelley RK, "Biomarker use in colorectal cancer therapy", J Natl Compr Canc Netw, 9, pp.1293~1302 (2011)
- Schmoll HJ, "ESMO Consensus Guidelines for management of patients with colon and rectal cancer. a personalized approach to clinical decision making", Ann Oncol, 23, pp.2479~2516 (2012)
- Van Cutsem E, "Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer : updated analysis of overall survival according to tumor KRAS and BRAF mutation status", J Clin Oncol, 29, pp.2011~2019 (2011)
- Andreyev HJ, "Kirsten ras mutations in patients with colorectal cancer : the multicenter"RASCAL"study", J Natl Cancer Inst, 90, pp.675~684 (1998)
- Hutchins G, "Value of mismatch repair, KRAS, and BRAF mutations in predicting recurrence and benefits from chemotherapy in colorectal cancer", J Clin Oncol, 29, pp.1261~1270 (2011)
- Toyota M, "Distinct genetic profiles in colorectal tumors with or without the CpG island methylator phenotype", Proc Natl Acad Sci U S A, 97, pp.710~715 (2000)
- Barault L, "Hypermethylator phenotype in sporadic colon cancer : study on a population-based series of 582 cases", Cancer Res, 68, pp.8541~8546 (2008)
- Ahn JB, "DNA methylation predicts recurrence from resected stage III proximal colon cancer", Cancer, 117, pp.1847~1854 (2011)
- Kim WY, "The regulation of INK4", ARF in cancer and aging, 2006, pp.127, 265~275
- Liggett WH Jr, "Role of the p16 tumor suppressor gene in cancer", J Clin Oncol, 16, pp.1197~1206 (1998)
- Bennecke M, "Ink4a", Arf and oncogene-induced senescence prevent tumor progression during alternative colorectal tumorigenesis, 2010, pp.18, 135~146
- Esteller M, "K-ras and p16 aberrations confer poor prognosis in human colorectal cancer", J Clin Oncol, 19, pp.299~304 (2001)
- Karamitopoulou E, "Expression of p16 in lymph node metastases of adjuvantly treated stage III colorectal cancer patients identifies poor prognostic subgroups : a retrospective analysis of biomarkers in matched primary tumor and lymph node metastases", Cancer, 116, pp.4474~4486 (2010)
- Bihl MP, "Characterization of CDKN2A(p16)methylation and impact in colorectal cancer : systematic analysis using pyrosequencing", J Transl Med, 10, pp.173~ (2012)
- Crea F, "Epigenetic mechanisms of irinotecan sensitivity in colorectal cancer cell lines", Mol Cancer Ther, 8, pp.1964~1973 (2009)
- Gallagher SJ, "p16INK4a expression and absence of activated B-RAF are independent predictors of chemosensitivity in melanoma tumors", Neoplasia, 10, pp.1231~1239 (2008)
- Finn RS, "Results of a randomized phase 2 study of PD 0332991, a cyclin-dependent kinase(CDK)4", 6 inhibitor, in combination with letrozole vs letrozole alone for first line treatment of ER+, Ann Oncol, pp.2012, 23(Suppl 2)[DOI]
- Samowitz WS, "Evaluation of a large, population-based sample supports a CpG island methylator phenotype in colon cancer", Gastroenterology, 129, pp.837~845 (2005)
- Shen L, "Association between DNA methylation and shortened survival in patients with advanced colorectal cancer treated with 5-fluorouracil based chemotherapy", Clin Cancer Res, 13, pp.6093~6098 (2007)
- Ogino S, "CpG island methylation, response to combination chemotherapy, and patient survival in advanced microsatellite stable colorectal carcinoma", Virchows Arch, 450, pp.529~537 (2007)
- Markl ID, "Global and gene-specific epigenetic patterns in human bladder cancer genomes are relatively stable in vivo and in vitro over time", Cancer Res, 61, pp.5875~5884 (2001)
- Claus R, "Quantitative DNA methylation analysis identifies a single CpG dinucleotide important for ZAP-70 expression and predictive of prognosis in chronic lymphocytic leukemia", J Clin Oncol, 30, pp.2483~2491 (2012)
- Douillard JY, "Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer", N Engl J Med, 369, pp.1023~1034 (2013)